miércoles, 6 de marzo de 2024

PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00325-X/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--rBmnOj1HHUzew8XJBTkNV8FZzxWUlhtODBVPQe0kzokR8vlN6KD-B05uDZRwBXvf3jQzvNWSlP6E_wdwoSM-_V7VKuA&_hsmi=296908066&utm_content=296876759&utm_source=hs_email

No hay comentarios:

Publicar un comentario